XML 15 R4.htm IDEA: XBRL DOCUMENT v3.21.2
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
3 Months Ended 9 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
OPERATING EXPENSES        
Research and development $ 6,231,908 $ 2,703,704 $ 17,985,937 $ 9,909,288
Financing costs (Notes 7 and 8) 16,667 197,102 18,147 500,972
General and administration 3,117,900 2,171,020 9,942,149 9,173,793
Total operating expenses (9,366,475) (5,071,826) (27,946,233) (19,584,053)
Foreign exchange (34,084) 10,937 (19,239) (685)
Interest income 80,394 172,346 155,293 478,952
Derivative liability gain (loss) (Note 9) 568,954 (36,285) (470,132) (60,242)
Loss for the period before taxes (8,751,211) (4,924,828) (28,280,311) (19,166,028)
Income tax recovery (expense) (800) 0 34,349 274,000
Loss and comprehensive loss for the period $ (8,752,011) $ (4,924,828) $ (28,245,962) $ (18,892,028)
Basic and diluted loss per common share $ (0.21) $ (0.24) $ (0.76) $ (0.91)
Weighted average number of common shares outstanding - basic and diluted 41,018,024 20,824,568 36,937,014 20,802,026